502
Participants
Start Date
January 31, 2016
Primary Completion Date
June 30, 2021
Study Completion Date
July 31, 2021
Ciforadenant
100 mg orally twice daily for the first 14 days of each 28-day cycle.
Ciforadenant
100 mg orally twice daily for 28 days of each 28-day cycle.
Ciforadenant
200 mg orally once daily for the first 14 days of each 28-day cycle.
Ciforadenant + atezolizumab
Ciforadenant 100 mg orally twice daily in combination with atezolizumab intravenously.
Ciforadenant
Start with 150mg orally twice daily for 28-day cycles; then, increase increments by 100mg/day for 6 dose levels.
Monash Health, Clayton
Royal Brisbane and Women's Hospital, Brisbane
Memorial Sloan Kettering Cancer Center, New York
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Medical Center Cancer Center, Pittsburgh
Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University School of Medicine, Baltimore
University of Miami Hospital and Clinics, Miami
Cleveland Clinic, Cleveland
Karmanos Cancer Institute, Detroit
Medical College of Wisconsin, Milwaukee
Rush University Medical Center, Chicago
University of Chicago Medical Center, Chicago
University of Arizona Cancer Center, Tucson
University of California - San Francisco, San Francisco
Stanford Cancer Institute, Stanford
Yale University, New Haven
Massachusetts General Hospital, Boston
Cross Cancer Institute, Edmonton
British Columbia Cancer Agency - Vancouver Centre, Vancouver
The Ottawa Hospital Cancer Centre, Ottawa
Lead Sponsor
Collaborators (1)
Genentech, Inc.
INDUSTRY
Corvus Pharmaceuticals, Inc.
INDUSTRY